RT Journal Article
SR Electronic
T1 GP73 is a glucogenic hormone regulating SARS-CoV-2-induced hyperglycemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.30.21256060
DO 10.1101/2021.04.30.21256060
A1 Wan, Luming
A1 Yang, Huan
A1 Li, Huilong
A1 Gong, Jing
A1 Deng, Yongqiang
A1 Ke, Yuehua
A1 Yang, Xiaopan
A1 Lin, Haotian
A1 Zhang, Yanhong
A1 Wang, Changjun
A1 Li, Dongyu
A1 Wang, Huapeng
A1 Peng, Yumeng
A1 Yan, Qiulin
A1 Huang, Linfei
A1 Wang, Xiaolin
A1 Gao, Qi
A1 Lin, Changqing
A1 Zheng, Fei
A1 Xu, Lei
A1 Liu, Jialong
A1 Zhang, Xuemiao
A1 Yang, Xiaoli
A1 Qin, Chengfeng
A1 Sun, Zhiwei
A1 Wu, Feixiang
A1 Wei, Congwen
A1 Zhong, Hui
YR 2021
UL http://medrxiv.org/content/early/2021/05/03/2021.04.30.21256060.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces new-onset diabetes and severe metabolic complications of pre-existing diabetes. The pathogenic mechanism underlying this is incompletely understood. Here, we provided evidence linking circulating GP73 with the exaggerated gluconeogenesis triggered by SARS-CoV-2 infection. We found that SARS-CoV-2 infection or glucotoxic condition increased the cellular secretion of GP73. Secreted GP73 trafficked to the liver and kidney to stimulate gluconeogenesis through cAMP/PKA pathway. By using global phosphoproteomics, we found a drastic remodeling of PKA kinase hub exerted by GP73. Notably, COVID-19 patients showed pathologically elevated plasma GP73, and neutralization of the secreted GP73 inhibited enhanced PKA signaling and glucose production associated with SARS-CoV-2 infection. GP73 blockade also reduced gluconeogenesis and lowered hyperglycemia in type 2 (T2D) diabetic mice. Therefore, our findings provide novel insight into the roles of GP73 as a key glucogenic hormone and mechanistic clues underlying the development of SARS-CoV-induced glucose abnormalities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank the National Key Research and Development Programme of China (grant no. 2018YFA0900800) and National Natural Science Foundation of China (grant nos. 31872715 32070755 81773205 and 82070595) for their support. Graphical abstract was created and exported with BioRender.com under a paid subscription.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of Huoshenshan Hospital approved the study (HSSLL036). Given the urgency of the COVID-19 pandemic, the need for informed consent forms was waived by the ethics boards of the hospitals. The Committee for Ethics in Human Studies from the Third Medical Center of the Chinese PLA General Hospital approved this study (KY2021-009).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Hui Zhong (towall{at}yahoo.com).